# A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

> **NCT03520959** · PHASE3 · TERMINATED · sponsor: **Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 1 (actual)

## Conditions studied

- Synovial Sarcoma
- Cancer
- Soft Tissue Sarcoma
- Sarcoma
- Metastatic Sarcoma

## Interventions

- **BIOLOGICAL:** LV305
- **BIOLOGICAL:** G305
- **OTHER:** LV305-matching placebo
- **OTHER:** G305-matching placebo

## Key facts

- **NCT ID:** NCT03520959
- **Lead sponsor:** Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-18
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-11-20
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was terminated due to sponsor's decision.
- **Last updated:** 2020-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520959, "A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03520959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*